SERPING1 and hereditary angioedema: Subcutaneous C1-INH (C1-INH [SC], HAEGARDA®, CSL Behring, Marburg, Germany) has been approved by the US Food and Drug Administration for routine prophylaxis to prevent HAE attacks in adolescents and adults [16].